IN8BIO INC

NASDAQ: INAB (IN8bio, Inc.)

Kemas kini terakhir: 20 jam lalu

0.790

-0.03 (-3.66%)

Penutupan Terdahulu 0.820
Jumlah Dagangan 11,693
Harga / Buku (P/B) 0.570
Julat 52 Minggu
0.724 (-8%) — 2.73 (245%)
EPS Cair (TTM) -13.20
Jumlah Hutang/Ekuiti (D/E MRQ) 30.79%
Nisbah Semasa (MRQ) 4.30
Aliran Tunai Operasi (OCF TTM) -19.35 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -8.68 M
Pulangan Atas Aset (ROA TTM) -73.25%
Pulangan Atas Ekuiti (ROE TTM) -174.66%

AISkor Stockmoo

-2.5
Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga turun. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Pegangan info NA
Sentimen Berita info NA
Institusi bersih -1.84% daripada saham dalam pemfailan 13F terkini: 5 pemegang menambah, 9 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat -82.7% dari 31 Aug hingga 30 Oct 2026, 1 hari untuk tutup (FINRA). info
Aktiviti Orang Dalam info NA
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Paras sokongan dan rintangan menurun. info
Skor Akhir -2.52
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok IN8bio, Inc. Bercampur Bercampur

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
INAB - - - 0.570 -2.5
HLVX 103 M - - 0.710 0.0
MEIP 49 M - - - 0.0
SONN 33 M - - 2.07 -1.4
ANIX - - - 6.26 -1.6
PLRX - - - 0.320 -3.8

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 4.20%
% Dimiliki oleh Institusi 20.95%

Pemilikan

Nama Tarikh Syer Dipegang
Texas Capital Bank Wealth Management Services Inc 30 Sep 2026 23,521

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 34.95%

Kedudukan Pemegang Saham
Bertambah 5 72,270
Berkurang 9 189,613
Baharu 2 10,936
Dijual habis 2 96,337

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 15,733 1.0
15 Oct 2026 32,797 1.0
30 Sep 2026 46,440 1.0
15 Sep 2026 63,110 2.2
31 Aug 2026 90,842 1.6
14 Aug 2026 139,903 1.4

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

1 Positif 0 Negatif 2 Neutral
Tarikh Jenis Butiran
16 Nov 2026 Yahoo Finance IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC) 50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group Median progression-free survival (mPFS) of 13.0…
06 Nov 2026 Yahoo Finance IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the…
05 Nov 2026 Yahoo Finance IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & DevelopmentReceived third-party recognition of INB-619 in a Nature Reviews Drug Discovery review of next-generation immune cell engagers for autoimmune diseaseRemain…
22 Sep 2026 Yahoo Finance IN8bio to Present at Sidoti Small-Cap Virtual Conference
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and…
10 Sep 2026 Yahoo Finance IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and…
09 Sep 2026 Yahoo Finance IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance…

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga turun.
Sokongan terdekat: 0.777 – 0.823 · paras sederhana
Rintangan terdekat: 0.847 – 0.983 · paras kukuh · kerap diuji, mungkin pecah

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda